MYH mutations are rare in prostate cancer

Shin, Eyun-Jung; Chappell, Edward; Pethe, Vaijayanti; Hersey, Karen; Kwast, Theodorus H. van der; Fleshner, Neil; Bapat, Bharati

doi:10.1007/s00432-006-0181-x

Cited by 7 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering other extracolonic cancer risks for MUTYH mutation carriers, we did not observe statistically significant evidence of an increased risk for cancers of the brain, pancreas, kidney, prostate and lung for monoallelic mutation carriers with a family history of CRC. Consistent with our results, Shin et al 43. and Agalliu et al 44.…”

Section: Discussionsupporting

confidence: 94%

Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer

Win

Cleary

Dowty

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

Cancer risks for a person who has inherited a MUTYH mutation from only one parent (monoallelic mutation carrier) are uncertain. Using the Colon Cancer Family Registry and Newfoundland Familial Colon Cancer Registry, we identified 2,179 first-and second-degree relatives of 144 incident colorectal cancer (CRC) cases who were monoallelic or biallelic mutation carriers ascertained by sampling population complete cancer registries in the United States, Canada and Australia. Using Cox regression weighted to adjust for sampling on family history, we estimated that the country-, age- and sex-specific standardized incidence ratios (SIRs) for monoallelic mutation carriers, compared to the general population, were: 2.04 (95% confidence interval, CI 1.56–2.70; p < 0.001) for CRC, 3.24 (95%CI 2.18–4.98; p < 0.001) for gastric cancer, 3.09 (95%CI 1.07–12.25; p = 0.07) for liver cancer and 2.33 (95%CI 1.18–5.08; p = 0.02) for endometrial cancer. Age-specific cumulative risks to age 70 years, estimated using the SIRs and US population incidences, were: for CRC, 6% (95%CI 5–8%) for men and 4% (95%CI 3–6%) for women; for gastric cancer, 2% (95%CI 1–3%) for men and 0.7% (95%CI 0.5–1%) for women; for liver cancer, 1% (95%CI 0.3–3%) for men and 0.3% (95%CI 0.1–1%) for women and for endometrial cancer, 4% (95%CI 2–8%). There was no evidence of increased risks for cancers of the brain, pancreas, kidney, lung, breast or prostate. Monoallelic MUTYH mutation carriers with a family history of CRC, such as those identified from screening multiple-case CRC families, are at increased risk of colorectal, gastric, endometrial and possibly liver cancers.

show abstract

Section: Discussionsupporting

confidence: 94%

Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer

Win

Cleary

Dowty

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…MYH interacts with apurinic/apyrimidinic endonuclease (APE) and proliferatingcell nuclear antigen (PCNA); furthermore, this enzyme excises adenine among G:A, G:A and C:A mismatched by 8-oxo, and then resects 8-oxo for repair by 8-oxoguanine DNA glycosylase (OGG1) (13,14). Mutations in MYH are involved in the initiation and progression of pulmonary, ovarian and gastrointestinal cancers, lymphoma and various other tumor types (5)(6)(7)(8)(9)(10).…”

Section: Discussionmentioning

confidence: 99%

“…8-oxoguanine (8-oxoG), which is generated from oxidative attack on guanine, is the most common form of oxidative DNA damage and displays a strong mutagenicity (3,4). One important enzyme that combats oxidative damage is MYH, a homolog of the transglucokinase Mut Y, which functions during DNA base excision repair and plays a significant role in the occurrence and development of various tumor types (5)(6)(7)(8)(9)(10). Since early detection of ESCC is difficult, with diffusion and metastasis typically occurring before diagnosis, we sought to determine whether MYH serves as a molecular marker for this disease.…”

Section: Introductionmentioning

confidence: 99%

Expression and clinical significance of the DNA repair enzyme MYH in esophageal squamous cell carcinoma

Shen

Chen

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. MYH is an important enzyme in combating DNA oxidative stress in the occurrence and development of various types of tumors. To investigate the correlation between expression of the DNA repair enzyme MYH in esophageal squamous cell carcinoma and 8-oxoguanine (8-oxoG) oxidative damage, as well as the clinical significance of altered MYH expression, tissues from 175 esophageal carcinoma cases were investigated in the present study. MYH expression and 8-oxoG oxidative damage in squamous cell carcinoma and adjacent normal tissue were assessed by immunohistochemistry and Western blotting. In 82.9% (145/175) of the cases, MYH protein expression in esophageal squamous cell carcinoma was lower than that of adjacent normal tissue (t=4.24, P<0.001). Additionally, 8-oxoG staining was higher in the tumors than in the normal tissue. Lower expression of MYH in esophageal squamous cell carcinoma was associated with depth of invasion, venous invasion, TNM stage and lymph node metastasis (P<0.05). In conclusion, a lower MYH expression level in esophageal cell carcinoma tissue was inversely associated with more severe 8-oxoG oxidative damage, suggesting that changes in MYH activity correspond to increased DNA damage in tumor cells. The use of MYH expression as a postoperative index for esophageal squamous cell carcinoma may guide the formulation of individualized chemotherapy for patients after surgery.

show abstract

“…Tumor types other than colorectal polyps and cancer that have been studied in relation to MUTYH variants include: gastric cancer [Goto et al, 2008;Kim et al, 2004;Tao et al, 2004;Zhang et al, 2006a], prostate cancer [Shin et al, 2007], bladder cancer [Figueroa et al, 2007;Huang et al, 2007], endometrial cancer [Barnetson et al, 2007], lung cancer [Al-Tassan et al, 2004], childhood leukemia [Akyerli et al, 2003], breast cancer [Beiner et al, 2009;Zhang et al, 2006b], hepatocellular carcinoma and cholangiocarcinoma [Baudhuin et al, 2006], and head and neck cancer [Görgens et al, 2007;Sliwinski et al, 2009]. So far, there are no reports of biallelic pathogenic MUTYH variants in the absence of a colorectal phenotype.…”

Section: Database Analysismentioning

confidence: 99%